A network pharmacology-guided multi-omics and spatial single-cell framework nominates WT1 as a spironolactone-linked immune biomarker in prostate cancer - PubMed
4 hours ago
- #spironolactone
- #prostate cancer
- #WT1
- Spironolactone (SPI) is a candidate for drug repurposing in prostate cancer (PCa) due to its anti-androgenic activity.
- The study uses network pharmacology, multi-omics, and spatial single-cell analysis to identify WT1 as a key biomarker linked to SPI in PCa.
- WT1 is downregulated in PCa tumors but high expression correlates with improved disease-free survival and an 'immune-hot' phenotype.
- scRNA-seq and spatial transcriptomics show WT1 is heterogeneously expressed in tumor and stromal compartments, particularly in immune-interacting niches.
- Molecular docking suggests potential SPI-WT1 interaction, and in vitro assays show WT1 restoration suppresses PCa cell proliferation and migration while inducing apoptosis.
- The study proposes the SPI-WT1 axis as a novel therapeutic target, positioning SPI as a potential immunomodulator in PCa treatment.